Viral Vectors Manufacturing Market Size, Status and Forecast to 2026
Gene therapy is one of the best treatment options for most chronic diseases. It involves inserting a functional copy of a gene into a defective cell. Gene therapy is useful in the treatment of cancers, inherited disorders, cardiovascular diseases, and infectious pathogen neurological disorders. Viral or non-viral vector methods are used in efficient transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.
Report Overview @ https://www.transparencymarketresearch.com/viral-vectors-manufacturing-market.html
Development of quality vectors in terms of formulation, physical size, cost, and delivery function is quite challenging. To minimize this problem, manufacturers use various approaches such as development of cell line culture, current good manufacturing practices, cell culture system, and expression systems that are used in the development of vectors. This is projected to boost the growth of the global viral vectors manufacturing market. Additionally, increase in the number of gene therapy candidates due to rapid development of diseases and rise in funding for gene therapies are expected to fuel the growth of the global viral vectors manufacturing market. The Alliance for Cancer Gene Therapy (ACGT) is a public charity foundation in the U.S. which funds for advancement in cancer gene therapies from laboratory to clinical trials. However, high cost of gene therapies and possible mutagenesis restrain the market.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49383
The global viral vectors manufacturing market can be segmented based on type, disease, application, and region. In terms of type, the global market can be divided into adenoviral vectors, retroviral vectors, adeno-associated viral vectors, and others. The retroviral vectors segment dominated the global viral vectors manufacturing market due to ease of application in major target diseases such as cancer and genetic disorders. Based on disease, the global viral vectors manufacturing market can be classified into cancers, infectious diseases, genetic disorders, and other diseases. The genetic disorders segment is anticipated to dominate the market due to increase in research activities on various genetic disorders such as sickle cell anemia, hemophilia A and B, and Huntington’s disease, and a strong gene therapy pipeline in the last phase of drug development. In terms of application, the global market can be bifurcated into gene therapy and vaccinology. The gene therapy segment is expected to account for the largest share of the market due to increase in the number of gene therapy clinical trials conducted for chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative diseases globally.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=49383
Geographically, the global viral vectors manufacturing market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region can be divide into specific countries/sub-regions such as the U.S., Canada, the U.K., Germany, Brazil, China, India, and GCC Countries. North America dominated the global viral vectors manufacturing market because of increase in research activities, large number of regenerative medicine companies, rise in prevalence of target diseases, and availability of funds. Asia Pacific is expected to be the most attractive market during the forecast period due to increase in health awareness and demand for advanced medical technology.
Key players operating in the global viral vectors manufacturing market are Lonza, Merck, Oxford BioMedica, CGT Catapult, Cobra Biologics, uniQure, FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec, and Spark Therapeutics, among others. These players adopt various strategies such as collaborations, agreements, partnerships, and launch of new products to gain competitive advantage in the market.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
Contact Us
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453